Tenofovir Alafenamide versus Tenofovir Disoproxil Fumarate: Systematic Review and Meta-Analysis

Abstract

Background: Highly active antiretroviral therapy (HAART) has greatly reduced morbidity and mortality. Despite the impact of antiretroviral therapy (ART), mortality in successfully treated HIV infected patients remains higher than in the general uninfected population, more specifically in Sub-Saharan Africa. In fact, ART has demonstrated toxicity. tenofovir disoproxil (TDF) is widely known, even so, TDF is known as nephrotoxic. Recently, tenofovir alafenamide (TAF) was found. TAF is a new oral prodrug of tenofovir, less toxic than TDF. TAF has potential intracellular accumulation; lower extracellular exposures of tenofovir may be realized with the potential to reduce off-target toxicities. Additionally, TAF has shown its efficacy in HIV-Hepatitis B co-infection.